For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Nabumetone is a non-steroidal anti-inflammatory drug. Nabumetone was developed by Beecham. It has many brand names such as Relaxen, Relifex and Gambaran. Nabumetone is a non-acidic NSAID, which is rapidly metabolized in the liver into the main active metabolite, 6-methoxy-2-naphthylacetic acid.
This report elaborates the market size, market characteristics, and market growth of the Nabumetone industry, and breaks down according to the type, application, and consumption area of Nabumetone. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Nabumetone in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
In addition, chapters 8-12 consider the impact of COVID-19 on the regional economy.
Key players in the global Nabumetone market covered in Chapter 13:
GlaxoSmithKline
Pfizer
In Chapter 6, on the basis of types, the Nabumetone market from 2015 to 2025 is primarily split into:
750 mg
500 mg
In Chapter 7, on the basis of applications, the Nabumetone market from 2015 to 2025 covers:
Osteoarthritis
Rheumatoid Arthritis
Geographically, the detailed analysis of production, trade of the following countries is covered in Chapter 4.2, 5:
United States
Europe
China
Japan
India
Geographically, the detailed analysis of consumption, revenue, market share and growth rate of the following regions are covered in Chapter 8, 9, 10, 11, 12:
North America (Covered in Chapter 8)
United States
Canada
Mexico
Europe (Covered in Chapter 9)
Germany
UK
France
Italy
Spain
Others
Asia-Pacific (Covered in Chapter 10)
China
Japan
India
South Korea
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 11)
Saudi Arabia
UAE
South Africa
Others
South America (Covered in Chapter 12)
Brazil
Others
Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025